Use of lipid-lowering drugs in NSTE-ACS patients after discharge - Summary of recommendations and evidence
In patients with a previous ACS diagnosis, LDL-c should be reduced to < 50 mg/dL, and HDL-c should be reduced to < 80 mg/dL.	I	B
When tolerated, preference should be given to high-intensity statins.	I	A
When the LDL-c target is not achieved with statins at the maximum tolerated dose, ezetimibe should be added.	I	A
PCSK9 inhibitors can be considered in patients who are receiving statin treatment at the highest tolerated dose, associated or not with ezetimibe, and who have not reached recommended LDL-c or HDL-c target levels.	IIa	A